Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Soliris
Soliris
Genentech posts long-term data on near-approval Soliris rival
Genentech posts long-term data on near-approval Soliris rival
Fierce Biotech
Genentech
satralizumab
Soliris
Alexion
NMOSD
Flag link:
Alexion plans phase 2 study of Soliris in COVID-19 in coming days: report
Alexion plans phase 2 study of Soliris in COVID-19 in coming days: report
Fierce Pharma
Alexion
COVID-19
clinical trials
Soliris
Flag link:
Apellis' blood disorder drug outdoes Alexion's Soliris in improving hemoglobin levels
Apellis' blood disorder drug outdoes Alexion's Soliris in improving hemoglobin levels
Reuters
Apellis Pharmaceuticals
Alexion Pharmaceuticals
PNH
pegcetacoplan
Soliris
Flag link:
Drugmakers rebranding around oncology, rare diseases could provide 2020 preview
Drugmakers rebranding around oncology, rare diseases could provide 2020 preview
Fierce Pharma
oncology
Rare Diseases
AstraZeneca
GSK
Alexion
Takeda
Soliris
Flag link:
Alexion to Buy Achillion in $930M Marriage of Rare Disease Drug Firms
Alexion to Buy Achillion in $930M Marriage of Rare Disease Drug Firms
Xconomy
Alexion Pharmaceuticals
Achillion
M&A
PNH
danicopan
Soliris
Flag link:
UCB strikes $2.5B deal to buy Ra for rival to Alexion's Soliris
UCB strikes $2.5B deal to buy Ra for rival to Alexion's Soliris
Fierce Biotech
UCB Pharma
Ra Pharmaceuticals
M&A
zilucoplan
Alexion
Soliris
Flag link:
After rocky hep C path, Achillion finds surer footing with FDA breakthrough status
After rocky hep C path, Achillion finds surer footing with FDA breakthrough status
Endpoints
Achillion
FDA
paroxysmal nocturnal hemoglobinuria
Soliris
PNH
Flag link:
Alexion shares slide on Amgen patent challenge to top-seller
Alexion shares slide on Amgen patent challenge to top-seller
Biopharma Dive
Amgen
Alexion
inter partes review
patents
Soliris
Flag link:
Alexion's beating forecasts with Soliris-to-Ultomiris switch. So what's up with its pesky stock price?
Alexion's beating forecasts with Soliris-to-Ultomiris switch. So what's up with its pesky stock price?
Fierce Pharma
Alexion
Soliris
Ultomiris
PNH
Flag link:
Alexion’s Soliris follow-up Ultomiris snares EU approval
Alexion’s Soliris follow-up Ultomiris snares EU approval
Pharmaforum
Alexion
Europe
Ultomiris
Soliris
patents
PNH
Flag link:
Alexion's cash cow Soliris just got fatter as FDA greenlights another blockbuster indication
Alexion's cash cow Soliris just got fatter as FDA greenlights another blockbuster indication
Endpoints
Alexion
Soliris
FDA
autoimmune disease
NMOSD
Flag link:
FDA Action Alert: Regeneron, Sanofi, Celgene
FDA Action Alert: Regeneron, Sanofi, Celgene
BioSpace
FDA
drug approvals
Acer Therapeutics
Edsivo
Regeneron
Sanofi
Dupixent
Celgene
Revlimid
Alexion
Soliris
Dova Pharmaceuticals
Doptelet
Nabriva Therapeutics
Contepo
Retrophin
Thiola
Flag link:
3 Drug Stocks That Could Win From Key FDA Approvals in June
3 Drug Stocks That Could Win From Key FDA Approvals in June
Motley Fool
Merck
Amag Pharmaceuticals
Alexion Pharma
FDA
Keytruda
Vyleesi
Soliris
Flag link:
Mark Your Calendar For These June PDUFA Dates
Mark Your Calendar For These June PDUFA Dates
Yahoo/Benzinga
FDA
Merck
Zerbaxa
XERIS
Gvoke HypoPen
Keytruda
Amag Pharmaceuticals
Palatin
Vyleesi
Acer Therapeutics
Edsivo
Sanofi
Regeneron
Dupixent
Alexion
Soliris
Retrophin
Thiola
Allergan
Botox
Flag link:
Go or no go? Merck, Regeneron and Alexion await US expansion
Go or no go? Merck, Regeneron and Alexion await US expansion
EP Vantage
Merck
Keytruda
Sanofi
Regeneron
Dupixent
Alexion
Soliris
FDA
Dova Pharmaceuticals
Retrophin
Flag link:
Alexion gets off to the races with key Ultomiris, Soliris launches
Alexion gets off to the races with key Ultomiris, Soliris launches
Fierce Pharma
Alexion
Ultomiris
Soliris
drug launches
Flag link:
14 Drugs Earn Billions for These Massachusetts Biotechs
14 Drugs Earn Billions for These Massachusetts Biotechs
BioSpace
Massachusetts
Boston
Biogen
Tecfidera
Benepali
Shire
Takeda
Vyvanse
Vertex Pharmaceuticals
Orkambi
Kalydeco
Alexion
Soliris
Strensiq
Sanofi Genzyme
Lantus
Ironwood Pharmaceuticals
Linzess
Flag link:
Alexion aims for fourth rare disease use for blockbuster Soliris
Alexion aims for fourth rare disease use for blockbuster Soliris
Pharmaforum
Alexion Pharmaceuticals
Soliris
neuromyelitis optica spectrum disorder
Flag link:
Alexion wins approval for rare disease drug, aims to switch patients from blockbuster Soliris
Alexion wins approval for rare disease drug, aims to switch patients from blockbuster Soliris
Stat
Alexion Pharmaceuticals
FDA
Ultomiris
Soliris
PNH
Flag link:
Ra Pharma files $100M round as Soliris rival clears phase 2 trial
Ra Pharma files $100M round as Soliris rival clears phase 2 trial
Fierce Biotech
Ra Pharma
Soliris
clinical trials
myasthenia gravis
zilucoplan
Flag link:
Pages
1
2
3
4
5
next ›
last »